Profile cover photo
Profile photo
The Oncologist
142 followers
142 followers
About
Posts

Post has attachment

Post has attachment

Post has attachment
A challenge in precision medicine is the identification of actionable driver mutations. Alterations can be identified within the tumor tissue, by small biopsy or fine‐needle aspirates, or by noninvasive methods, such as circulating tumor cells or circulating tumor DNA. This article presents a case of atypical neuroendocrine tumor metastatic to the bone and brain for which circulating tumor DNA analysis found an ALK translocation.

Post has attachment

Post has attachment
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations
http://ow.ly/7UiL30dLk9k
Photo

Post has attachment

Post has attachment
Targeted drug delays relapse of intermediate-stage lung cancer -

Post has attachment
Shorter Duration of Trastuzumab May Reduce Cardiac Toxicity, Costs | ASCO Annual Meeting http://ow.ly/cIN730cmK6G

Post has attachment

Post has attachment
FDA granted accelerated approval to brigatinib (ALUNBRIG tablets, Takeda Pharmaceutical Company Limited, through its wholly owned subsidiary ARIAD Pharmaceuticals, Inc.) for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
Wait while more posts are being loaded